Deutsche Bank AG Has $1.27 Million Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Deutsche Bank AG increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 46.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,082 shares of the company’s stock after purchasing an additional 10,839 shares during the period. Deutsche Bank AG owned approximately 0.07% of Amphastar Pharmaceuticals worth $1,265,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Pacer Advisors Inc. increased its position in shares of Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after acquiring an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp lifted its position in Amphastar Pharmaceuticals by 81.4% in the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock valued at $36,347,000 after acquiring an additional 439,281 shares in the last quarter. Boston Partners acquired a new position in Amphastar Pharmaceuticals in the 4th quarter worth $15,778,000. Wealthfront Advisers LLC bought a new position in Amphastar Pharmaceuticals during the 4th quarter worth about $9,268,000. Finally, Dimensional Fund Advisors LP increased its holdings in Amphastar Pharmaceuticals by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company’s stock worth $44,503,000 after purchasing an additional 105,288 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the transaction, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 5,231 shares of company stock valued at $142,752. 27.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wells Fargo & Company cut their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, May 8th. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $32.33.

Amphastar Pharmaceuticals Trading Up 1.1%

Shares of NASDAQ:AMPH opened at $24.47 on Monday. The company’s 50-day moving average price is $25.20 and its two-hundred day moving average price is $32.82. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The stock has a market capitalization of $1.16 billion, a PE ratio of 8.16, a price-to-earnings-growth ratio of 2.19 and a beta of 0.78.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.